In this study labeling EDTMP (ethylenediamine tetra(methylene phosphonic acid)) and HEDP (Hydroxyethylidene-1, 1-Diphosphonic Acid) as the carrier ligands with Scandium-47 were investigated. The biokinetics of the bone seeking of labeled ligands with Scandium-47 were assessed by measuring the skeletal absorbed dose and then the mice data extrapolated to human absorbed dose and compared with the Rhenium-HEDP, Samarium-EDTMP dosimetry data estimated by other researchers. Because the availability of Sc was limited we performed some preliminary studies using Sc.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.apradiso.2017.07.062 | DOI Listing |
Asian Pac J Cancer Prev
December 2024
Department of Biotechnology and Molecular Medicine, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Background: One key feature that distinguishes cancerous cell populations from their normal counterparts is a heightened tendency towards uncontrolled growth and invasive activity. Therapeutic techniques like radiotherapy can impact the viability and invasive behavior of cancer cells by modifying the structure of DNA and inducing programmed cell death.
Methods: This research is an experimental study and involved a comprehensive investigation into the effects of 6MV X-ray radiotherapy on various absorbed doses (ranging from 4 to 10 Gy by steps 2Gy) on toxicity, migration, and colony formation in C6 glioblastoma cellular cultures.
Eur J Nucl Med Mol Imaging
December 2024
Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, Bern, 3010, Switzerland.
Purpose: Long axial field-of-view (LAFOV) positron emission tomography/computed tomography (PET/CT) scanners enable high sensitivity and wide anatomical coverage. Therefore, they seem ideal to perform post-selective internal radiation therapy (SIRT) Y scans, which are needed, to confirm that the dose is delivered to the tumors and that healthy organs are spared. However, it is unclear to what extent the use of LAFOV PET is feasible and which dosimetry approaches results in accurate measurements.
View Article and Find Full Text PDFEJNMMI Res
December 2024
μNEURO Research Centre of Excellence, Universiteitsplein 1, University of Antwerp, Antwerp, Belgium.
Background: Huntington's disease (HD) is a rare neurodegenerative disorder caused by an expansion of the CAG trinucleotide repeat in the huntingtin gene which encodes the mutant huntingtin protein (mHTT) that is associated with HD-related neuropathophysiology. Noninvasive visualization of mHTT aggregates in the brain, with positron emission tomography (PET), will allow to reliably evaluate the efficacy of therapeutic interventions in HD. This study aimed to assess the radiation burden of [F]CHDI-650, a novel fluorinated mHTT radioligand, in humans based on both in vivo and ex vivo biodistribution in mice and subsequent determination of dosimetry for dosing in humans.
View Article and Find Full Text PDFProbl Radiac Med Radiobiol
December 2024
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, 45 Vasylkivska Str., Kyiv, 03022, Ukraine.
The introduction of new radiation technologies in modern radiotherapy of cancer patients is still in some cases associated with the risk of developing early and distant complications in healthy tissues surrounding the tumour. The causes of their occurrence, pathogenesis and radiobiological characteristics are reviewed and briefly described. The rate of the manifestation of complications depends on the radiosensitivity of tissues and is determined by the amount of absorbed dose of ionizing radiation.
View Article and Find Full Text PDFEur J Drug Metab Pharmacokinet
December 2024
Preclinical Development-Drug Metabolism and Pharmacokinetics, Bayer AG, Berlin, Germany.
Background: Elinzanetant is a dual neurokinin-1,3 receptor antagonist in development for the treatment of menopausal vasomotor symptoms. The objectives of these studies were to characterize the mass balance and biotransformation of elinzanetant.
Methods: In the clinical evaluation, whole blood, plasma, urine, and feces were collected from healthy fasted male volunteers (n = 6) following a single dose of 120 mg [C]-elinzanetant oral suspension for analysis of total radioactivity and metabolite profiling.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!